An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB has announced the publication of preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression in cancer. The study, led by Professor Douglas Hanahan, showed that blocking IL1RAP with a nadunolimab surrogate antibody can overcome resistance to immune therapy in a cervical cancer model. These findings are supported by clinical data showing nadunolimab’s potential to reduce immunosuppressive myeloid cells, suggesting its broader potential in cancer treatment. The research highlights the role of IL-1 family cytokines in systemic immunosuppression and the potential of nadunolimab to enhance the efficacy of cancer vaccines and improve immunotherapy outcomes.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. It has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s oncology program includes the antibody nadunolimab (CAN04), studied primarily in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia also has a second development program, CAN10, targeting autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.